Medannex Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 4

Medannex General Information

Description

Operator of a biopharmaceutical company intended to improve the lives of people impacted by cancers and autoimmune diseases. The company specializes in developing antibodies that specifically target and inhibit annexin-A1 as well as help to modulate the innate and adaptive immune systems to treat diseases, enabling physicians to treat their patients in an enhanced way.

Contact Information

Website
www.medannex.org
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Lochrin Square
  • 92-98 Fountainbridge
  • Edinburgh EH3 9QA
  • Scotland, United Kingdom
+44 0131
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 1 Lochrin Square
  • 92-98 Fountainbridge
  • Edinburgh EH3 9QA
  • Scotland, United Kingdom
+44 0131

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Medannex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 27-Oct-2020 Completed Clinical Trials - Phase 1
7. Grant 15-Jun-2020 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series B) 28-Aug-2019 Completed Clinical Trials - Phase 1
5. Later Stage VC Completed Clinical Trials - Phase 1
4. Grant 21-Feb-2019 Completed Clinical Trials - Phase 1
3. Grant 12-Jun-2018 Completed Startup
2. Later Stage VC 31-Mar-2017 $1.57M $2.84M Completed Startup
1. Seed Round 27-Aug-2013 $1.27M $1.27M Completed Startup
To view Medannex’s complete valuation and funding history, request access »

Medannex Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Preference 83,190 $0.000012 $1.46 $1.46 1x $1.46 0.28%
To view Medannex’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Medannex Patents

  • 31

    Total Documents Applications and Grants

  • Total Patents Families

  • 15

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Medannex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202208893-D0 Combination therapy for cancer Inactive 16-Jun-2022
GB-202116680-D0 Combination therapy for cancer Inactive 18-Nov-2021
CA-3238416-A1 Combination therapy for cancer Pending 18-Nov-2021
AU-2022389646-A1 Combination therapy for cancer Pending 18-Nov-2021
EP-4433171-A1 Combination therapy for cancer Pending 18-Nov-2021 A61K39/3955
To view Medannex’s complete patent history, request access »

Medannex Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Medannex Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Morningside Group Venture Capital Minority
Innovate UK Government
Scottish Enterprise Government Minority
Elixir Ventures Venture Capital Minority
To view Medannex’s complete investors history, request access »

Ready to get started?

Request a free trial

Medannex FAQs

  • When was Medannex founded?

    Medannex was founded in 2009.

  • Where is Medannex headquartered?

    Medannex is headquartered in Edinburgh, United Kingdom.

  • What is the size of Medannex?

    Medannex has 12 total employees.

  • What industry is Medannex in?

    Medannex’s primary industry is Drug Discovery.

  • Is Medannex a private or public company?

    Medannex is a Private company.

  • What is Medannex’s current revenue?

    The current revenue for Medannex is .

  • How much funding has Medannex raised over time?

    Medannex has raised $16.2M.

  • Who are Medannex’s investors?

    Morningside Group, Innovate UK, Scottish Enterprise, and Elixir Ventures have invested in Medannex.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »